Septic myocardial injury represents a critical challenge in emergency and critical care medicine today. This condition occurs when systemic inflammation triggers profound cardiac dysfunction during severe infections. Consequently, clinicians are increasingly exploring adjunctive therapies like Xuebijing (XBJ) to improve patient outcomes. Recent research highlights how XBJ alleviates septic myocardial injury by targeting iron-induced cell death mechanisms.

The ICAM1/TLR Pathway in Septic Myocardial Injury

Specifically, the study utilized LPS-induced models to examine molecular triggers of heart damage. It found that ICAM1 expression rises significantly during sepsis, which subsequently activates Toll-like receptor (TLR) signaling. This activation leads to a surge in inflammatory cytokines and accelerates cardiomyocyte apoptosis. However, XBJ effectively suppresses ICAM1, thereby inhibiting the overactivated TLR pathway. Furthermore, XBJ reduces levels of biomarkers such as cTnI and BNP, which serve as reliable indicators of cardiac stress.

Inhibiting Iron Death and Oxidative Stress

Beyond inflammation, XBJ addresses iron death mediated by proteins like TFR1 and ASCL4. This process, also known as ferroptosis, contributes heavily to myocardial tissue degradation. By restoring glutathione (GSH) levels and decreasing malondialdehyde (MDA), XBJ provides a robust antioxidant effect. Consequently, cardiomyocytes demonstrate improved survival rates even under high-stress conditions. Therefore, XBJ serves as a multi-target agent capable of tackling inflammation and iron-mediated damage simultaneously.

What is the primary mechanism of Xuebijing in sepsis?

Xuebijing functions by inhibiting inflammatory responses and reducing iron-mediated cell death (ferroptosis) via the ICAM1/TLR signaling pathway.

Which cardiac biomarkers are reduced by XBJ?

Research indicates that XBJ treatment can lower levels of cTnI, BNP, and CK-MB, which are key indicators of myocardial damage.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to be a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Meng X et al. Xuebijing alleviates septic myocardial injury by inhibiting iron death mediated by the ICAM1/TLR signaling pathway. Histol Histopathol. 2026 Apr 23. doi: 10.14670/HH-25-079. PMID: 42023484.


2. Li X, et al. Ferroptosis in Sepsis: Mechanisms and Potential Therapeutic Targets. Front Immunol. 2021.


3. Wang Y, et al. The efficacy of Xuebijing injection in the treatment of sepsis: A systematic review and meta-analysis. Trials. 2019.